Search results for "INHIBITOR"

showing 10 items of 3742 documents

Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat

2018

0301 basic medicinemedicine.medical_specialtyCancer ResearchLymphomaMice03 medical and health sciences0302 clinical medicineHematology; Oncology; Cancer ResearchInternal medicineTumor MicroenvironmentmedicineAnimalsHumansHeparanase030212 general & internal medicineEnzyme InhibitorsGlucuronidaseHematologyChemistryGeneral MedicineHematologyXenograft Model Antitumor AssaysNeoplasm Proteins030104 developmental biologyOncologyCancer research
researchProduct

The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review

2017

Cardiovascular disease (CVD) is the leading cause of death worldwide, and so the search for innovative and accurate biomarkers for guiding prevention, diagnosis, and treatment is a valuable clinical and economic endeavor. Due to a recent findings that the serum concentration of mitochondrial ATP synthase inhibitory factor 1 (IF1) is an independent prognostic factor in patients with coronary heart disease (CHD), we reviewed the role of this protein in myocardial ischemic preconditioning, its correlation to plasma high density lipoprotein (HDL), the predictive potential in patients with CHD, and its interplay with angiogenesis. IF1 has been positively correlated with plasma HDL-cholesterol, a…

0301 basic medicinemedicine.medical_specialtyClinical chemistryAngiogenesisEndocrinology Diabetes and MetabolismInhibitory factor 1Clinical BiochemistryHigh density lipoproteinCoronary DiseaseClinical nutritionDiseaseReview030204 cardiovascular system & hematologyBioinformaticsMitochondrial Proteins03 medical and health scienceschemistry.chemical_compoundAngiogenesis; Cardiovascular disease; High density lipoprotein; Inhibitory factor 10302 clinical medicineEndocrinologyHigh-density lipoproteinInternal medicineMedicineHumansCause of deathBiochemistry medicalbiologybusiness.industryBiochemistry (medical)ProteinsCardiovascular diseaseMitochondria030104 developmental biologyEndocrinologychemistrybiology.proteinIschemic preconditioningApolipoprotein A1AngiogenesisbusinessLipids in Health and Disease
researchProduct

Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis

2021

Background & Aims A number of double, triple, and quadruple therapies have been proposed as first-line empiric treatments for Helicobacter pylori infection. However, knowledge of their worldwide and regional comparative efficacy is lacking. We examined the comparative effectiveness of all empirically used first-line regimens tested against standard triple treatment using a network meta-analysis of published randomized controlled trials. Methods Data extracted from eligible randomized controlled trials were entered into a Bayesian network meta-analysis to investigate the comparative efficacy of H pylori infection empiric first-line regimens and to explore their effectiveness rank order. The …

0301 basic medicinemedicine.medical_specialtyComparative Effectiveness ResearchTime FactorsEfficacyVonoprazanSettore MED/12 - GASTROENTEROLOGIANetwork Meta-Analysislaw.inventionHelicobacter Infections03 medical and health sciences0302 clinical medicineRandomized controlled trialDrug TherapyLevofloxacinlawInternal medicinemedicineHumansFirst-Line RegimensRandomized Controlled Trials as TopicHepatologybiologyHelicobacter pyloribusiness.industryRemission InductionSettore MED/09 - MEDICINA INTERNAGastroenterologyBayes TheoremProton Pump InhibitorsOdds ratioHelicobacter pyloribiology.organism_classificationConfidence intervalAnti-Bacterial AgentsTreatmentRegimen030104 developmental biologyTreatment OutcomeMeta-analysisCombination030211 gastroenterology & hepatologyDrug Therapy Combinationbusinessmedicine.drug
researchProduct

Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP)

2020

Abstract Acute and chronic physical exercises may enhance the development of statin-related myopathy. In this context, the recent (2019) guidelines of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) for the management of dyslipidemias recommend that, although individuals with dyslipidemia should be advised to engage in regular moderate physical exercise (for at least 30 min daily), physicians should be alerted with regard to myopathy and creatine kinase (CK) elevation in statin-treated sport athletes. However it is worth emphasizing that abovementioned guidelines, previous and recent ESC/EAS consensus papers on adverse effects of statin therapy as wel…

0301 basic medicinemedicine.medical_specialtyConsensusSports medicineContext (language use)Physical exercise03 medical and health sciences0302 clinical medicineAthlethsMuscular DiseasesStatin intoleranceMedicineHumansAdverse effectAthlethExerciseMylagiaDyslipidemiasPharmacologybiologybusiness.industryAthletesExercisesAthleths Exercises Management Mylagia Statin intolerance.Athleths; Exercises; Management; Mylagia; Statin intolerancemedicine.diseasebiology.organism_classificationManagement030104 developmental biologyAthletes030220 oncology & carcinogenesisPhysical therapyPosition paperStatin therapyHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemia
researchProduct

The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes

2020

ABSTRACT Introduction The dipeptidyl peptidase-4 inhibitors (DPP-4is), which belong to the class of incretin-based medications, are recommended as second or third-line therapies in guidelines for the management of type 2 diabetes mellitus. They have a favorable drug tolerability and safety profile compared to other glucose-lowering agents. Objective This review discusses data concerning the use of DPP-4is and their cardiovascular profile, and gives an updated comparison with the other oral glucose-lowering medications with regards to safety and efficacy. Currently available original studies, abstracts, reviews articles, systematic reviews and meta-analyses were included in the review. Discu…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismIncretin030209 endocrinology & metabolismType 2 diabetesSaxagliptinLinagliptinIncretins03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicinemedicineHumansHypoglycemic AgentsVildagliptinDipeptidyl-Peptidase IV InhibitorsPancreatitiHypoglycemic Agentbusiness.industryPancreatic NeoplasmIncretinmedicine.diseasePancreatic NeoplasmsTreatment Outcome030104 developmental biologyDiabetes Mellitus Type 2PancreatitischemistryTolerabilitySitagliptinDipeptidyl-Peptidase IV InhibitorbusinessAlogliptinHumanmedicine.drugMetabolism
researchProduct

Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures

2019

Summary Guidance is provided in an international setting on the assessment and specific treatment of postmenopausal women at low, high and very high risk of fragility fractures. Introduction The International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of osteoporosis in 2019. This manuscript seeks to apply this in an international setting, taking additional account of further categorisation of increased risk of fracture, which may inform choice of therapeutic approach. Methods Clinical perspective and updated literature search. Results The following areas are reviewed: …

0301 basic medicinemedicine.medical_specialtyFRAXEndocrinology Diabetes and MetabolismeducationOsteoporosisPsychological interventioninhibitors of bone resorption030209 endocrinology & metabolismRisk AssessmentAnabolic agents03 medical and health sciencesTherapeutic approach0302 clinical medicineBone DensityRisk FactorsTreatment of osteoporosisInternal medicinemedicinefracture risk assessmentHumansanabolic agentsIntensive care medicineOsteoporosis PostmenopausalAgedAnabolic agents Fracture risk assessment FRAX Inhibitors of bone resorption Treatment of osteoporosisddc:616Postmenopausal womenbusiness.industryCorrectionFracture risk assessmentInhibitors of bone resorptionMiddle Agedtreatment of osteoporosismedicine.diseaseRheumatologyIncreased riskFemalePosition Paper030101 anatomy & morphologybusinessVery high riskAlgorithmsOsteoporotic FracturesFRAXOsteoporosis International
researchProduct

Shortened Activated Partial Thromboplastin Time May Help in Diagnosing Hereditary and Acquired Angioedema

2016

<b><i>Objective:</i></b> To evaluate whether activated partial thromboplastin time (APTT) could be used in the laboratory diagnosis of hereditary or acquired angioedema (HAE or AAE) with and without C1 inhibitor (C1-INH) deficiency. <b><i>Methods:</i></b> In a prospective investigation, APTT and other coagulation parameters were determined in 149 adult patients with various types of angioedema and in 26 healthy participants (HP). <b><i>Results:</i></b> Mean APTT was significantly shortened in HAE-C1-INH type I (p < 0.0001) and type II (p = 0.0017) and in AAE-C1-INH (p < 0.0001) compared to the HP. APTT was shorten…

0301 basic medicinemedicine.medical_specialtyImmunologyAcquired angioedemaGastroenterologyC1-inhibitorDiagnosis Differential03 medical and health sciencesPredictive Value of TestsInternal medicinemedicineHumansImmunology and Allergyheterocyclic compoundsProspective StudiesAngioedemaProspective cohort studyBlood CoagulationBlood coagulation testAngioedemamedicine.diagnostic_testbiologybusiness.industryAngioedemas HereditaryComplement C4General Medicinerespiratory systembacterial infections and mycosesrespiratory tract diseases030104 developmental biologyCoagulationPredictive value of testsAnesthesiaImmunologybiology.proteinPartial Thromboplastin TimeBlood Coagulation Testsmedicine.symptombusinessComplement C1 Inhibitor ProteinBiomarkerscirculatory and respiratory physiologyPartial thromboplastin timeInternational Archives of Allergy and Immunology
researchProduct

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response:…

2021

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response.Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers.Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbation…

0301 basic medicinemedicine.medical_specialtyMedicine (General)Settore MED/16 - REUMATOLOGIAmedicine.drug_classtumor necrosis factor inhibitorsbiologic therapy interleukin-1 inhibitors personalized medicine tocilizumab tumor necrosis factor inhibitors tumor necrosis factor receptor-associated periodic syndromeinterleukin-1 inhibitorsGastroenterology03 medical and health scienceschemistry.chemical_compoundtocilizumab0302 clinical medicineTocilizumabR5-920Internal medicinemedicinebiologic therapyAdverse effecttumor necrosis factor receptor-associated periodic syndromeOriginal Research030203 arthritis & rheumatologyAnakinraProteinuriabiologymedicine.diagnostic_testbusiness.industryC-reactive proteinGeneral MedicineTumor necrosis factor receptor associated periodic syndromepersonalized medicineCanakinumab030104 developmental biologychemistryErythrocyte sedimentation ratebiology.proteinAutoinflammationCorticosteroidMedicinemedicine.symptombusinessmedicine.drugbiologic therapy; interleukin-1 inhibitors; personalized medicine; tocilizumab; tumor necrosis factor inhibitors; tumor necrosis factor receptor-associated periodic syndrome
researchProduct

A Stage-Based Approach to Therapy in Parkinson’s Disease

2019

Parkinson’s disease (PD) is a neurodegenerative disorder that features progressive, disabling motor symptoms, such as bradykinesia, rigidity, and resting tremor. Nevertheless, some non-motor symptoms, including depression, REM sleep behavior disorder, and olfactive impairment, are even earlier features of PD. At later stages, apathy, impulse control disorder, neuropsychiatric disturbances, and cognitive impairment can present, and they often become a heavy burden for both patients and caregivers. Indeed, PD increasingly compromises activities of daily life, even though a high variability in clinical presentation can be observed among people affected. Nowadays, symptomatic drugs and non-phar…

0301 basic medicinemedicine.medical_specialtyParkinson's diseaseImpulse control disorderlcsh:QR1-502ReviewDiseasel-dopaBiochemistryREM sleep behavior disorderMotor symptomslcsh:MicrobiologyAntiparkinson Agentsnon-pharmacological therapy03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationmedicineHumansdopamine-agonistsApathyanticholinergicsResting tremorMolecular Biologyamantadinebusiness.industryAmantadineParkinson Diseasemonoamine oxidase inhibitorsmotor symptomsmedicine.diseasenon-motor symptoms030104 developmental biologyacetylcholinesterase inhibitorsParkinson’s disease<span style="font-variant: small-caps">l</span>-dopaSettore MED/26 - Neurologiamedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugBiomolecules
researchProduct

Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nona…

2017

Abstract Aims: Nonalcoholic steatohepatitis (NASH) is characterized by steatosis, panlobular inflammation, liver fibrosis, and increased cardiovascular mortality. Dipeptidyl peptidase-4 inhibitors (gliptins) are indirect glucagon-like peptide 1 agonists with antidiabetic and anti-inflammatory activity, used for the treatment of type 2 diabetes. Their potential and underlying mechanisms to treat metabolic liver inflammation and fibrosis as well as the associated vascular dysfunction remain to be explored. Results: In the methionine/choline-deficient (MCD) diet and Mdr2−/− models of NASH and liver fibrosis, treatment with sitagliptin and linagliptin significantly decreased parameters of steat…

0301 basic medicinemedicine.medical_specialtyPhysiologyClinical BiochemistryAnti-Inflammatory AgentsGene ExpressionInflammationType 2 diabetes030204 cardiovascular system & hematologymedicine.disease_causeBiochemistryAntioxidantsProinflammatory cytokineMice03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisInternal medicinemedicineAnimalsMyeloid CellsMolecular BiologyDipeptidyl peptidase-4General Environmental ScienceInflammationMice KnockoutDipeptidyl-Peptidase IV Inhibitorsbusiness.industryMacrophagesCell BiologyMacrophage Activationmedicine.diseaseFibrosisDietDisease Models AnimalOxidative Stress030104 developmental biologyEndocrinologyLiverNADPH Oxidase 2General Earth and Planetary SciencesTumor necrosis factor alphaSteatosismedicine.symptomReactive Oxygen SpeciesbusinessBiomarkersOxidative stressAntioxidants &amp; Redox Signaling
researchProduct